Phase i study of prolonged-Infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: Tolerability of an optimal dose schedule

Oncology

Volumn 77, Issue 1, 2009, Pages 63-70

  Estephan, Fadi ^a,b   Valero, Vicente ^a   Esteva, Francisco J ^a   Mejia, Jaime A ^a   Frye, Debra K ^a   Ibrahim, Nuhad K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Advanced breast cancer; Cyclophosphamide; Gemcitabine; Phase I

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; ONDANSETRON; PROCHLORPERAZINE MALEATE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; BREAST TUMOR; CANCER STAGING; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REMISSION; SALVAGE THERAPY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649216835     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226213     Document Type: Article

References (25)

1. Plunkett W, Huang P, Searcy CE, Gandhi V: Gemcitabine: preclinical pharmacology and mechanism of action. Semin Oncol 1996;23:3-15.
2. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(suppl 11):3-10.
3. Huang P, Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 1995: 22(suppl 11):19 -25.
4. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, et al: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-2736.
5. Salman HS, Tanaka K, Sparano JA: Phase I/ II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. Clin Breast Cancer 2002;2:299-303.
6. Levin M, Durgam S, Novetsky A: Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer. Cancer Invest 2002;20:872-875.
7. Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al: A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline and taxane-refractory breast cancer patients. Oncology 2002;62:25-32.
8. Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al: Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triple combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study. Semin Oncol 2001;28(suppl 10):50-56.
9. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K, et al: Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999;10:525-531.
10. Schmid P, Akrivakis K, Flath B, et al: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999;10:625-631.
11. Kleinman MB, Stewart I, Ratmanskiy S, Gayle M, Bonomi P: Phase II trial of prolonged-infusion gemcitabine as second line treatment in non-small-cell lung cancer. J Clin Oncol 2004;22:7316.
12. Kornblith P, Wells A, Gabrin MJ, Piwowar J, George LD, Ochs RL, et al: Breast cancer response rates to chemotherapeutic agents studied in vitro. Anticancer Res 2003;23:3405-3411.
13. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-262.
14. Grunewald R, Kantarjian H, Du M, et al: Gemcitabine in leukemia: a phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 1992;10:406-413.
15. Gandhi V, Plunkett W, Du M, et al: Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002;20:665-673.
16. Tempero M, Plunkett W, Ruiz Van Haperen V, et al: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.
17. Ghandi V: Questions about gemcitabine dose rate: answered or unanswered? J Clin Oncol 2007;25:5691-5694.
18. Veltkamp S, Beijnen JH, Schellens J: Prolonged versus standard gemcitabine infusion: translation molecular pharmacology to new treatment strategy. Oncologist 2008;13:261-276.
19. Schmid P, Schweigert M, Beinert T, et al: Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I study. Invest New Drugs 2005;23:139-146.
20. Zwitter M, Kovac V, Smrdel U, et al: Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005;16:1129-1134.
21. Rajdev L, Goldberg G, Hopkins U, et al: A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. Med Oncol 2006;23:369-376.
22. Cappuzo F, Novello S, De Marinis F, et al: A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 2006;52:319-325.
23. Gridelli C, Gallo C, Ceribelli A, et al: Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the Gemcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007;8:500-512.
24. Giovannetti E, Del Tacca M, Mey V, et al: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival of pancreas cancer patients treated with gemcitabine. Cancer Res 2006;66:3928-3935.
25. Spratlin J, Sangha R, Glubrecht D, et al: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004;10:6956-6961.